Duchenne-focused biotech Sarepta loses $6.5B in value after trial fail

Shares of Sarepta Therapeutics Inc., which employs more than 600 people in Massachusetts, were cut in half Friday after the failure of a highly anticipated gene therapy for Duchenne muscular dystrophy.